TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07895498: A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 122 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$10,718,400

Rescue Site Savings

+$7,068,600

Unlock Full NCT07895498 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07895498 Rescue Dossier →